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Abstract
Background
The aim of this study was to investigate inequalities in survival for non-Hodgkin’s lymphoma
(NHL), distinguishing between direct and indirect effects of patient, social and process-of-
care factors.
Methods
All cases of NHL diagnosed in Ireland in 2004–2008 were included. Variables describing
patient, cancer, stage and process of care were included in a discrete-time model of survival
using Structural Equation Modelling software.
Results
Emergency admissions were more common in patients with co-morbid conditions or with
more aggressive cancers, and less frequent for patients from more affluent areas. Aggres-
sive morphology, female sex, emergency admission, increasing age, comorbidity, treatment
in a high caseload hospital and late stage were associated with increased hazard of mortal-
ity. Private patients had a reduced hazard of mortality, mediated by systemic therapy,
admission to high caseload hospitals and fewer emergency admissions.
Discussion
The higher rate of emergency presentation, and consequent poorer survival, of uninsured
patients, suggests they face barriers to early presentation. Social, educational and cultural
factors may also discourage disadvantaged patients from consulting with early symptoms of
NHL. Non-insured patients, who present later and have more emergency admissions would
benefit from better access to diagnostic services. Older patients remain disadvantaged by
sub-optimal treatment, treatment in non-specialist centres and emergency admission.
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Introduction
International studies have shown a rapid increase in incidence of non-Hodgkin’s lymphoma
(NHL) [1–5] in many countries from the early 1970s onwards and significant improvements
in survival from the mid 1990s [2,3,6–9]. Survival differences persist between countries [6],
although they are smaller than for many solid tumours. Differences in NHL survival by sex,
ethnicity and socio-economic status are also observed within countries [10–16]. While some
differences in survival between groups may be due to differences in tumour biology [17], most
are probably attributable to differences between groups in underlying health and in the use of,
access to, and experience of, health services. Poorer outcomes may be related to age, sex, mari-
tal status, ethnicity, relative poverty, geographical isolation or social isolation and may be exac-
erbated by conscious or unconscious discrimination in health service access, operation or
configuration [18–22].
Investigation of the impact of these factors on survival should distinguish between direct
and indirect effects of personal attributes and differential access to services. Factors like
comorbidity or age may have direct effects on survival or may operate indirectly via associa-
tions with, for example, treatment. Deprived patients may have financial, cultural or transport
difficulties in accessing diagnostic or treatment services and may suffer discriminatory treat-
ment by health providers [23]. Conventional survival modelling can control for these factors—
insofar as they are measurable—but cannot provide information on the complex pathways
through which deprivation influences survival, or on the relative magnitudes of these indirect
effects; this information is only available if direct and indirect influences are distinguished.
Without this information, action to mitigate deprivation may be targeted inappropriately.
The aim of this study was to investigate inequalities in survival for patients diagnosed with
NHL, distinguishing between direct and indirect effects of patient, social and health service-
related factors. The methodology used in this paper is particularly suited to the study of sur-
vival in NHL, which is close to that of all cancers combined [24] and is strongly dependent on
age, stage and treatment. We have attempted to overcome the limitations of current models by
using an alternative analytical approach. This involves extending Structural Equation Model-
ling to include survival outcomes, via an innovative discrete-time specification of the hazard.
This has allowed us to explore the complex relationships between variables and to distinguish
between direct and indirect effects on survival.
Methods
All cases of NHL registered by the Irish National Cancer Registry as incident during the years
2004–2008 were included. Patients registered with a subsequent invasive cancer (other than
non-melanoma skin cancer) between 1/1/2004 and 31/12/2011 were excluded as it was not
possible to determine which cancer would be the cause of death. Completeness of registration
of cancer at the Registry has been estimated to be at least 97–98% [25].
Registry data were linked, using probabilistic matching on name, address and date of birth,
to public hospital discharge data from the Hospital Inpatient Enquiry (HIPE) for all patients
admitted to public hospitals [26]. 86% of cases could be linked in this way to at least one HIPE
record. The public/private status of patients (i.e. if they paid directly, or through health insur-
ance, for some or all of their treatment or diagnostic procedures) is recorded in the HIPE data
for patients admitted to public hospitals. Patients admitted to private hospitals only did not
have a HIPE record and were classified as “private”. Patients who attended both public and
private hospitals for their cancer treatment were assigned one of these two categories on the
basis of their longest admission.
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The type of initial admission (scheduled or emergency) was determined from HIPE data, as
was co-morbidity. HIPE data includes information on up to 19 co-morbid conditions for each
discharge and this information was used to assign a Charlson comorbidity score [27], exclud-
ing NHL, for each patient. No admission type or Charlson score could be assigned to patients
(380, 13.6%) who were never admitted to a public hospital, and therefore had no HIPE record;
these patients were assigned a Charlson score of 0 and defined as scheduled admissions.
Information on patient age, address, sex and marital status, tumour stage (Ann Arbor) and
grade (indolent or aggressive, based on histological type) at diagnosis was provided by the Reg-
istry. Stage information was missing in 14.7% of cases and was assigned using the EM algo-
rithm. Lymphomas were classified as “aggressive” if the ICDO3 morphology [28] was
described as any of the following: mantle cell lymphoma; malignant lymphoma (mixed small
and large cell), diffuse; malignant lymphoma (large B-cell), diffuse; malignant lymphoma
(large B-cell), diffuse, immunoblastic, NOS; Burkitt lymphoma, NOS; follicular lymphoma,
grade 3; mature T-cell lymphoma, NOS; angioimmunoblastic T-cell lymphoma; anaplastic
large cell lymphoma, T-cell and Null cell type; hepatosplenic gamma-delta cell lymphoma;
intestinal T-cell lymphoma; NK/T-cell lymphoma, nasal and nasal-type; precursor cell lym-
phoblastic lymphoma, NOS; or precursor T-cell lymphoblastic lymphoma. 913 cases were
coded as 9590/3 and 9591/3 (NHL or malignant lymphoma, not otherwise specified) and were
their grade was classified as “unknown”; the remainder of histological types were classified as
“indolent”. A Pobal (HP) area-based deprivation score was assigned to each case, based on the
census small area of residence (average population ~230 persons) at the time of diagnosis [29].
This score was unknown in 8.0% of cases, and was assigned using the EM algorithm. Popula-
tion density of the area of residence was obtained from the 2006 census of population (www.
cso.ie) [30] and used as a measure of urban/rural residence. Addresses were also assigned to
one of four Health Service Executive (HSE) Regions, two of which include Dublin and two
which cover the South and West of the country. These regions are largely self-sufficient with
regard to adult cancer services.
Active cancer-directed treatment was defined as systemic therapy, radiotherapy or surgery,
where the primary aim was to destroy, or reduce the extent of, the lymphoma. Treatment was
classified as “any systemic therapy” (chemotherapy, immunotherapy, targeted therapy) or
“other” (radiotherapy, surgery or no active tumour-directed treatment). The hospital of main
treatment was determined for each patient from National Cancer Registry data. In most cases,
this was the hospital in which the patient had systemic therapy; for patients who did not have
systemic therapy, the main hospital was that of radiotherapy, any other tumour-directed treat-
ment or diagnosis. Caseload for the main hospital was calculated as the annual average number
of patients with NHL admitted (whether or not they had active tumour-directed treatment)
during the study period. The highest quartile of caseload (four hospitals treating >30 patients/
year) was defined as “high caseload”.
Registry data were linked to official death certificate data from the Central Statistics Office.
Deaths were classified as either due to NHL, or to other causes, using an algorithm developed
by the Scottish Cancer Registry [31]. The censoring date was 31/12/2012.
Survival was modelled using a discrete-time survival model using only time-invariant
covariates with constant hazards. The methods have been described in detail previously [32].
All models were estimated using version 5.21 of the software package MPlus using the MLR
estimator [33]. This allows the specification of a complex model including direct and indirect
effects. The structure of the model is illustrated in Fig 1, using the typical conventions for path
diagrams. These are modelled by assuming that there is a normally-distributed latent response
variable underlying each ordinal dependent variable. The discrete values of the categorical var-
iable coincide with thresholds on the scale of this latent variable or liability factor. The first
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component of the model comprises 24 dichotomous indicators containing quarterly survival
data, covering six years from the moment of diagnosis, and a latent hazard factor which cap-
tures the propensity of death during each interval. The second component consists of the
remaining variables, grouped into eight blocks: patient characteristics, tumour characteristics,
contextual measures, year of diagnosis, stage of disease, type of admission, systemic therapy
and hospital caseload. The last four of these are considered as describing the process of care,
and the others the background characteristics of the patient and cancer. The model assumes
that the background characteristics influence the stage of the cancer at the moment of diagno-
sis (i.e. early/late diagnosis), whilst treatment optimality is influenced, once again, by back-
ground characteristics, the stage of the disease, the caseload of the hospital where treatment is
received and the route by which the patient entered the hospital. Caseload and entry route are
also regressed on the background characteristics, with a view to exploring their role as mediat-
ing factors. Finally, the survival prospects of the patient depend on the combined effect of all of
these influences.
Fig 1. Model structure.
doi:10.1371/journal.pone.0168684.g001
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In order to simplify interpretation of the indirect effects, we report the results of a model
which specifies classical linear regression equations for all dependent variables, regardless of
their measurement scale (with the exception of the dichotomous survival outcome, which is
modelled using a standard logit specification). A sensitivity analysis was carried out and con-
firms that the sign and p-values for model coefficients are not unduly influenced by this
specification.
Results
Study population
2,793 cases of NHL, incident in 2004–2008, were included in the analysis (Table 1). 54% of
patients were male and 63% were aged under 70. The majority (58%) were married and two-
thirds (64%) attended hospital solely, or predominantly, as public patients. 41% of cancers
were at Ann Arbor stage I or II at diagnosis, and 41% were classified as having aggressive mor-
phology. 79% of patients had no recorded comorbid conditions and 19% were admitted as an
emergency. Just over two-thirds (68%) had systemic therapy, either alone or in combination;
23% had no active cancer-directed treatment.
Associations between background characteristics and process variables
The association of background patient and cancer characteristics with four process-of-care
variables—stage, emergency admission, hospital caseload and systemic therapy—is shown in
Table 2.
Presentation at late (III/IV) stage increased significantly over the study period. Late stage
was more frequent for female patients and older patients, and those with one or more comor-
bidities; it was less frequent in those living in more affluent areas and for more aggressive lym-
phomas. Emergency admissions with lymphoma decreased significantly during the study
period and were more common in patients with one or more co-morbid conditions or with
more aggressive cancers, and less frequent for patients from more affluent areas, or living in
the Dublin North-East and South HSE regions.
Treatment in high caseload hospitals was more common for patients with one or more
comorbidities, and for those living in the HSE West region; it was less common for private
patients, for those living outside urban areas and for those presenting as an emergency. Sys-
temic therapy was more frequent for married patients, those living in the South and West HSE
regions and for patients with more aggressive or late stage lymphomas. Systemic therapy was
less common for private patients and for those admitted to hospital as emergency cases.
Effects on survival
Tables 3 and 4 show the direct and indirect effects, respectively, of both background and
process-of-care variables on the hazard, expressed as logit coefficients. Factors associated with
an increased hazard of mortality were, in decreasing order of effect size, aggressive morphol-
ogy, female sex, emergency admission, increasing age, comorbidity, residence in the South
HSE region, treatment in a high caseload hospital and late stage. The hazard of mortality was
significantly reduced by systemic therapy and private patient status, after controlling for the
other variables. In terms of indirect effects, married patients had a reduced hazard of mortality,
which was mediated by a higher rate of systemic therapy. Affluence also reduced the hazard
indirectly, by reducing late stage and emergency admission, and private patients had a reduced
hazard mediated through systemic therapy, admission to high caseload hospitals and fewer
emergency admissions. The indirect effects were statistically significant for marital status and
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affluence, but for private patients the negative effect of lower rates of systemic therapy largely
cancelled out the positive impact of admission to higher caseload hospitals and reduced emer-
gency admissions.
Discussion
This study illustrates the complexity of the pathways leading to better or worse survival pros-
pects for patients with NHL. Many of the determinants of survival identified in this study are
Table 1. Patient, cancer and treatment characteristics (N = 2,793).
Variable Value Number of cases (%)
year of incidence 2004 542 (19.4%)
2005 511 (18.3%)
2006 576 (20.6%)
2007 571 (20.4%)
2008 593 (21.2%)
age at diagnosis <60 1083 (38.8%)
60–69 677 (24.2%)
70–79 661 (23.7%)
80+ 372 (13.3%)
sex male 1500 (53.7%)
female 1293 (46.3%)
marital status married 1613 (57.8%)
unmarried 1180 (42.2%)
main category of care (private or public) public 1776 (63.6%)
private 1017 (36.4%)
HSE area Dublin Mid Leinster 778 (27.9%)
Dublin North East 568 (20.3%)
South 732 (26.2%)
West 701 (25.1%)
urban/rural residence urban 986 (35.3%)
intermediate 598 (21.4%)
rural 943 (33.8%)
unknown 266 (9.5%)
grade of tumour indolent 734 (26.3%)
aggressive 1146 (41.0%)
unknown 913 (32.7%)
comorbidities none/unknown 2210 (79.1%)
1 or more 583 (20.9%)
tumour stage Stage I 704 (25.2%)
Stage II 432 (15.5%)
Stage III 622 (22.3%)
Stage IV 625 (22.4%)
unknown 410 (14.7%)
first hospital admission type planned 2265 (81.1%)
emergency 528 (18.9%)
main treatment in high-caseload hospital no 2098 (75.1%)
yes 695 (24.9%)
systemic therapy no 884 (31.7%)
yes 1909 (68.3%)
doi:10.1371/journal.pone.0168684.t001
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well-established in the literature—age, socio-economic characteristics, stage, cancer aggres-
siveness and comorbidity [10,12,13,16,34]. Living in a more affluent area had no significant
direct effect on the hazard of mortality, but nevertheless exerted a significant indirect effect,
mediated by a lower probability of late stage and emergency presentation. Private patients also
had a lower hazard of mortality, but for different reasons [35]—a direct reduction of the haz-
ard, probably due to lower levels of unrecorded comorbidity [36,37] and indirect effects due to
lower rates of emergency admission and, somewhat unexpectedly, the fact that admission to
higher caseload hospitals was associated with a higher hazard. Private patients were less likely
to have systemic therapy, which led to an increase in the hazard of mortality.
The negative impact of higher hospital caseload on survival may be due to differences in
case-mix not captured by this analysis. We could find only one study of the effects of caseload
on NHL outcome [38]; this looked at physician caseload and found no effect. Patients admitted
Table 2. Regression coefficients (beta) of optimum treatment, caseload, tumour stage and first hospital admission type on background variables.
Significant results (p<0.05) are shown in bold.
stage III/IV emergency admission caseload>30 cases/year systemic therapy
Background variables
Sex male 0.00 (ref)) 0.00 (reference class) 0.00 (reference class) 0.00 (reference class)
female 0.53 (0.22, 0.84) 0.00 (-0.12, 0.12) -0.06 (-0.20, 0.08) 0.00 (-0.12, 0.12)
age each 10 years 0.09 (0.05, 0.13) 0.00 (-0.02, 0.02) -0.01 (-0.03, 0.01) -0.06 (-0.08, -0.04)
older men all females; males aged <70 0.00 (reference class) 0.00 (reference class) 0.00 (reference class) 0.00 (reference class)
males 70+ -0.07 (-0.13, -0.01) 0.00 (-0.02, 0.02) 0.01 (-0.01, 0.03) 0.00 (-0.02, 0.02)
affluence per unit score -0.33 (-0.60, -0.06) -0.19 (-0.29, -0.09) 0.07 (-0.05, 0.19) 0.04 (-0.08, 0.16)
marital status unmarried 0.00 (reference class) 0.00 (reference class) 0.00 (reference class) 0.00 (reference class)
married 0.02 (-0.06, 0.10) -0.01 (-0.05, 0.03) 0.00 (-0.04, 0.04) 0.10 (0.06, 0.14)
public/private status public 0.00 (reference class) 0.00 (reference class) 0.00 (reference class) 0.00 (reference class)
private -0.06 (-0.16, 0.04) -0.03 (-0.07, 0.01) -0.08 (-0.12, -0.04) -0.05 (-0.09, -0.01)
comorbidities none 0.00 (reference class) 0.00 (reference class) 0.00 (reference class) 0.00 (reference class)
one or more 0.15 (0.05, 0.25) 0.10 (0.06, 0.14) 0.08 (0.04, 0.12) 0.00 (-0.04, 0.04)
area of residence Dublin Mid Leinster 0.00 (reference class) 0.00 (reference class) 0.00 (reference class) 0.00 (reference class)
Dublin North east 0.00 (-0.12, 0.12) -0.04 (-0.08, 0.00) 0.03 (-0.01, 0.07) 0.03 (-0.03, 0.09)
South -0.08 (-0.20, 0.04) -0.10 (-0.14, -0.06) 0.02 (-0.02, 0.06) 0.05 (0.01, 0.09)
West 0.01 (-0.11, 0.13) 0.00 (-0.04, 0.04) 0.10 (0.06, 0.14) 0.07 (0.01, 0.13)
urban/rural residence urban 0.00 (reference class) 0.00 (reference class) 0.00 (reference class) 0.00 (reference class)
intermediate 0.07 (-0.05, 0.19) 0.02 (-0.02, 0.06) -0.07 (-0.11, -0.03) -0.01 (-0.05, 0.03)
rural 0.03 (-0.09, 0.15) 0.03 (-0.01, 0.07) -0.13 (-0.17, -0.09) -0.01 (-0.05, 0.03)
unknown -0.03 (-0.19, 0.13) 0.05 (-0.01, 0.11) -0.11 (-0.17, -0.05) -0.02 (-0.08, 0.04)
tumour grade low 0.00 (reference class) 0.00 (reference class) 0.00 (reference class) 0.00 (reference class)
high -0.14 (-0.24, -0.04) 0.10 (0.06, 0.14) 0.04 (0.00, 0.08) 0.22 (0.18, 0.26)
year of diagnosis per year 0.05 (0.01, 0.09) -0.02 (-0.04, 0.00) -0.01 (-0.03, 0.01) 0.00 (-0.02, 0.02)
Process variables
stage I/II - 0.00 (reference class) 0.00 (reference class) 0.00 (reference class)
III/IV - 0.04 (0.02, 0.06) 0.01 (-0.01, 0.03) 0.01 (-0.01, 0.03)
emergency admission no 0.00 (reference class) - 0.00 (reference class) 0.00 (reference class)-
yes 0.04 (0.02, 0.06) - 0.01 (-0.01, 0.03) -0.70 (-0.74, -0.66)
hospital caseload <30 cases/year 0.00 (reference class) 0.00 (reference class) - 0.00 (reference class)
30 cases+ per year 0.01 (-0.01, 0.03) 0.01 (-0.01, 0.03) - -0.01 (-0.05, 0.03)
systemic therapy no 0.00 (reference class) 0.00 (reference class)- 0.00 (reference class)
yes 0.01 (-0.01, 0.03) -0.70 (-0.74, -0.66) -0.01 (-0.05, 0.03)
doi:10.1371/journal.pone.0168684.t002
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to high caseload hospitals had a higher level of comorbidity, which was controlled for in this
analysis, but it is probable that higher caseload hospitals simply see more complex patients.
This complexity may not be fully captured by the comorbidity data available in the HIPE sys-
tem and the difference in comorbidity between patients in high and low caseload hospitals
may be greater than measured here. It should also be noted that only a small number of hospi-
tals were classified as “high caseload” and the finding may be chance.
Although poorer survival and lower treatment rates are often accepted as inevitable results
of ageing and increasing co-morbidity, systemic therapy and radiotherapy for NHL are gener-
ally well tolerated by older patients [39,40]. We found that systemic therapy was associated
with significantly better survival. Older patients in this study were significantly less likely to
have systemic therapy, had poorer survival and were less likely to be admitted to a high
Table 3. Direct effects (beta) of patient, cancer and treatment characteristics on the hazard.
Variable Value Hazard coefficient (95% confidence
intervals)
Background variables
sex male 0 (reference)
female 1.00 (0.20, 1.80)
age each 10 years 0.44 (0.34, 0.54)
older men (age*sex
interaction)
all females; males aged
<70
0 (reference)
males 70+ -0.12 (-0.24, 0.00)
affluence per unit score -0.02 (-0.41, 0.37)
marital status unmarried 0 (reference)
married -0.04 (-0.20, 0.12)
public/private status public 0 (reference)
private -0.19 (-0.35, -0.03)
comorbidities none 0 (reference)
one or more 0.41 (0.23, 0.59)
area of residence Dublin Mid Leinster 0 (reference)
Dublin North east 0.01 (-0.21, 0.23)
South 0.35 (0.15, 0.55)
West -0.07 (-0.29, 0.15)
area population density urban 0 (reference)
intermediate 0.02 (-0.20, 0.24)
rural 0.10 (-0.10, 0.30)
unknown 0.14 (-0.11, 0.39)
tumour grade indolent 0 (reference)
aggressive 1.02 (0.80, 1.24)
year of diagnosis per year -0.04 (-0.10, 0.02)
Process variables
stage at diagnosis I/II 0 (reference)
III/IV 0.24 (0.18, 0.30)
emergency admission No 0 (reference)
Yes 0.68 (0.50, 0.86)
hospital caseload <30 cases/year 0 (reference)
30 cases+ per year 0.21 (0.05, 0.37)
systemic therapy No 0 (reference)
Yes -0.53 (-0.69, -0.37)
doi:10.1371/journal.pone.0168684.t003
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caseload hospital. Under-treatment of older patients, not explained by co-morbidity, has been
frequently reported [41–43] and may reflect attitudes and beliefs both within and outside the
health services. Although being married had no independent direct effect on hazard, it had a
significant indirect effect, as married patients were more likely to have systemic therapy. Asso-
ciations between marital status and survival are increasingly reported [17,44–47], but this anal-
ysis suggests that these are not direct effects but rather because married patients are more
likely to receive optimal treatment [48,49], possibly due to intervention by family members
[50].
The reasons for poorer outcomes in NHL patients who present as an emergency are
unclear. The proportion of emergency admissions in this study was lower (19% as opposed to
27%) than in a recent large English study [51], which also showed an increase in emergency
admission with increasing deprivation. However, we had no information on type of admission
for 13.6% of patients, so 19% may be an under-estimate. Unlike the English study, we found
no sex difference, after adjustment, in the proportion of emergency admissions. Initial man-
agement of elective and emergency lymphomas was similar (data not shown), but there may
have been complexities in emergency management not captured here. Significantly more
comorbidity was recorded for emergency admissions, but this (as well as stage) was controlled
for in the analysis. Not all relevant prognostic data can be routinely recorded by cancer regis-
tries [37], and more in-depth analysis (likely involving primary data collection) will be needed
to better understand the effects of emergency presentation.
Patients from more affluent areas, and those treated privately (i.e. with private health insur-
ance), had fewer emergency admissions, and consequently better survival, although private
Table 4. Indirect effects (beta, logit coefficient) of patient, cancer and treatment characteristics on hazard.
Hazard
married (.v. unmarried) affluence (per unit score) private patient (.v. public)
systemic therapy -0.05 (-0.08, -0.03) -0.02 (-0.08, 0.04) 0.03 (0.01, 0.05)
high caseload 0.00 (-0.01, 0.01) 0.01 (-0.01, 0.04) -0.02 (-0.03, 0.00)
late stage 0.00 (-0.02, 0.02) -0.08 (-0.14, -0.01) -0.02 (-0.04, 0.01)
emergency admission -0.01 (-0.03, 0.01) -0.13 (-0.20, -0.05) -0.02 (-0.04, 0.00)
high caseload! systemic therapy <0.01 0.00 (0.00, 0.00) <0.01
late stage! systemic therapy <0.01 0.04 (0.00, 0.08) <0.01
late stage!high caseload <0.01 <0.01 <0.01
late stage!emergency admission <0.01 -0.01 (-0.02, 0.00) <0.01
emergency admission! systemic therapy <0.01 -0.01 (-0.01, 0.00) <0.01
emergency admission!high caseload <0.01 0.01 (0.00, 0.01) <0.01
late stage!high caseload! systemic therapy <0.01 <0.01 <0.01
late stage!emergency admission! systemic therapy <0.01 <0.01 <0.01
late stage!emergency admission!high caseload <0.01 <0.01 <0.01
late stage!emergency admission!high caseload! systemic
therapy
<0.01 <0.01 <0.01
All indirect effects -0.06 (-0.09, -0.02) -0.18 (-0.28, -0.07) -0.02 (-0.06, 0.01)
Direct effect* -0.04 (-0.20, 0.12) 0.08 (-0.41, 0.57) -0.19 (-0.35, -0.03)
Total effect -0.10 (-0.25, 0.06) -0.10 (-0.60, 0.39) -0.21 (-0.37, -0.05)
Each cell shows the indirect effects of the column variable on hazard, as mediated through the row variable e.g. the change in hazard of being married, due
to receipt of systemic therapy, is -0.05 (-0.08, -0.03).
Statistically significant hazards are shown in bold.
* as shown in Table 2
doi:10.1371/journal.pone.0168684.t004
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health insurance was not related to stage at diagnosis. The higher rate of emergency presenta-
tion by uninsured patients suggests that they face greater barriers to earlier presentation. This
is unlikely to be at primary care level, as all patients, with the exception of those with the lowest
income, must pay a fee of about €60 per visit (and this is generally not covered by health insur-
ance). Hospital waiting times for public patients are lengthy in Ireland [52, 53]. The Irish
health system is a very complex mixed public-private system. All residents have access to low-
cost secondary care (including all phases of cancer treatment) with small co-payments, but
many purchase private health insurance and health care, which tend to coincide. About 44% of
the population held private health insurance at the time of the study [54]; this generally covers
inpatient care in private hospitals, and inpatient care as a private patient of a consultant in a
public hospital.
Emergency presentation may occur if the patient has severe systemic symptoms or obstruc-
tive symptoms due to extranodal disease. For the majority of patients, however, symptoms are
insidious and non-specific, and an enlarged lymph node or other mass is usually the first diag-
nostic sign [55]. As with breast [56, 57] and testicular [58–60] cancer, socio-economic factors
may lead to cultural and educational differences causing delay before presenting with a lump.
These delays may contribute to late or emergency presentation. Patients may also present to
different specialties, either medical or surgical, which has the potential to generate further
delays in diagnosis and treatment.
Overall, we observed significant disparities in stage at diagnosis and treatment of NHL due
to socio-economic status, whether based on area of residence or health insurance. The effect of
measures at individual level differed from those measured at the area level, as the latter may
have been mediated by geographical factors such as proximity to hospitals and local availability
of general practitioners. Clearly, measures constructed at the area and individual levels provide
different insights and both should be used whenever possible.
The impact of deprivation on survival is well known, but the mechanisms through which it
exerts its effects have been difficult to elucidate. This is at least partly due to the limitations of
conventional regression and survival models. The limitations of routinely collected registry
data, such as we use here, to examine the causes of socio-economic variation in survival have
also been well described [37]. Patients in lower socio-economic groups, or living in “deprived”
areas, have been shown to present later [16,17], to have higher levels of co-morbidity [12,17]
and to be less likely to have radiotherapy [12,61]. These factors are clearly inter-related [19]
but few studies have attempted to unravel the complex configurations of risk factors that
appear to be at work. This can be adequately described only by using a more flexible class of
statistical model, such as that used in this analysis. A key finding of this study is that depriva-
tion may influence outcomes in multiple ways, each of which needs an appropriate and tar-
geted form of intervention. These models can not only quantify the importance of different
pathways, but can also illustrate areas where more information would lead to better
understanding.
As already mentioned, a key limitation of this type of study is its retrospective nature and
dependence on routinely collected data. The factors determining a patient’s decision to seek
help for symptoms, the doctor’s decision to investigate and shared decisions on treatment are
complex, and need to be explored. We were also limited by significant amounts of missing
data, again inevitable in a registry based study. The fact that all co-morbidity data was missing
for patients with no public hospital stays was particularly limiting, although sensitivity analysis
showed that imputed values for these patients gave almost identical coefficients. The use of
public/private inpatient status as a proxy for health insurance status may also be a weakness,
but given the high costs of inpatient private care it is unlikely that many patients would have
opted to pay these from their own resources.
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These findings could be strengthened by more focussed patient-centred research [23,62–
65] to identify the pathways leading to emergency and non-emergency presentation, and their
consequences for treatment and outcomes; to gain better insights into the processes of shared
decision-making on treatment and how these are affected by age, co-morbidity and socio-
economic status; and to develop more sensitive measures of comorbidity and fitness for
treatment.
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